CC vs ECL

For growth investors, Ecolab Inc.

(ECL) is the stronger pick with 2. 2% revenue growth year-over-year, versus 0. 4% for The Chemours Company (CC). Ecolab Inc. (ECL) offers the better valuation at 36. 2x trailing P/E (31. 5x forward), making it the more compelling value choice. Analysts rate Ecolab Inc. (ECL) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, The Chemours Company is actually cheaper at 16.

4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ecolab Inc.

(ECL) delivered a total return of +20. 3%, compared to -19. 1% for The Chemours Company (CC). Over 10 years, the gap is even starker: CC returned +205. 3% versus ECL's +142. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ecolab Inc.

(ECL) is the lower-risk stock at 0. 63β versus The Chemours Company's 1. 92β — meaning CC is approximately 207% more volatile than ECL relative to the S&P 500. On balance sheet safety, Ecolab Inc. (ECL) carries a lower debt/equity ratio of 96% versus 18% for The Chemours Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ecolab Inc.

(ECL) is pulling ahead at 2. 2% versus 0. 4% for The Chemours Company (CC). On earnings-per-share growth, the picture is similar: Ecolab Inc. grew EPS -1. 2% year-over-year, compared to -549. 1% for The Chemours Company. Over a 3-year CAGR, ECL leads at 4. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ecolab Inc.

(ECL) is the more profitable company, earning 12. 9% net margin versus -6. 6% for The Chemours Company — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ECL leads at 18. 1% versus -0. 1% for CC. At the gross margin level — before operating expenses — ECL leads at 44. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Chemours Company (CC) trades at 16.

4x forward P/E versus 31. 5x for Ecolab Inc. — 15. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ECL: 24. 2% to $327. 11.

All stocks in this comparison pay dividends.

The Chemours Company (CC) offers the highest yield at 2. 2%, versus 1. 0% for Ecolab Inc. (ECL).

For long-horizon retirement investors, Ecolab Inc.

(ECL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), 1. 0% yield, +142. 1% 10Y return). The Chemours Company (CC) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ECL: +142. 1%, CC: +205. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.